Brief: MaxCyte Q4 Revenue USD 8.7 Million Vs. IBES Estimate USD 7.93 Million
11/03/2025 20:05
Mar 11 (Reuters) - MaxCyte Q4 adjusted EBITDA USD -11.8 million. Q4 gross profit USD 6.4 million Q4 operating expenses USD 19.3 million Q4 net income USD -10.6 million
Recent news on MaxCyte
See all newsCell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
Brief: MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
MaxCyte Inc reports results for the quarter ended June 30 - Earnings Summary
MaxCyte Q2 revenue beats estimates
MaxCyte Inc expected to post a loss of 9 cents a share - Earnings Preview